Z Contains A Cyclopentyl Or Cyclopentene Ring Patents (Class 514/530)
  • DRUG DELIVERY THROUGH HYDROGEL PLUGS
    Publication number: 20100209478
    Abstract: An embodiment is a medical prosthesis for blocking or reducing tear flow through a punctum or canaliculus of a human eye and delivering a drug to the eye that comprises a dehydrated covalently crosslinked synthetic hydrophilic polymer hydrogel with dimensions to pass through a puncta lacrimali, with the dehydrated hydrogel absorbing physiological water to swell to at least 1 mm in cross-sectional width and conformably fit a canaliculus, with the hydrogel comprising a therapeutic agent dispersed through the hydrogel for release to an eye, with the hydrogel having a water content of at least about 50% by weight or volume when allowed to fully hydrate in vitro in physiological saline.
    Type: Application
    Filed: February 12, 2010
    Publication date: August 19, 2010
    Inventors: Amarpreet S. Sawhney, Peter Jarrett, Michael Bassett, Charles Blizzard
  • SUSTAINED RELEASE DELIVERY OF ONE OR MORE AGENTS
    Publication number: 20100209477
    Abstract: The lacrimal implant delivery systems and methods described herein provide for controlled release of a therapeutic agent for the treatment of disease, including the treatment of glaucoma, ocular hypertension, or elevated intraocular pressure with latanoprost or other anti-glaucoma agents. Treatment of disease, including glaucoma, ocular hypertension, or elevated intraocular pressure with latanoprost or other anti-glaucoma agent in conjunction with penetration enhancer, such as benzalkonium chloride, and/or artificial tears is also provided.
    Type: Application
    Filed: January 22, 2010
    Publication date: August 19, 2010
    Applicant: QLT PLUG DELIVERY INC.
    Inventors: ZUHAL BUTUNER, Deepank Utkhede, Sylvie Sim, David J. Wiseman
  • Acetals of nepetalic acid and method of preparation
    Patent number: 7776912
    Abstract: Disclosed are acetals of nepetalic acid. They may be prepared by reaction of an alcohol with nepetalic acid, and are useful as repellents for insects and arthropods, in addition to other uses.
    Type: Grant
    Filed: June 27, 2007
    Date of Patent: August 17, 2010
    Assignee: E.I. du Pont de Nemours and Company
    Inventors: Mark A. Scialdone, Ann Y. Liauw
  • Methods of treating HIV infection
    Patent number: 7776863
    Abstract: The invention encompasses pharmaceutical compositions and methods for using Compound 1 in combination with other agents for treating patients with AIDS or HIV infection.
    Type: Grant
    Filed: February 24, 2005
    Date of Patent: August 17, 2010
    Assignee: Bristol-Myers Squibb Company
    Inventors: Pin-Fang Lin, Beata Nowicka-Sans, Gregory Yamanaka
  • PHARMACEUTICALS FOR XEROSIS
    Publication number: 20100204320
    Abstract: A method for preventing or treating xerosis by applying a prostaglandin D receptor selective agonist to a mammal.
    Type: Application
    Filed: April 19, 2010
    Publication date: August 12, 2010
    Applicants: Taisho Pharmaceutical Co., Ltd., Fumie Sato
    Inventors: Iwao ARAI, Nobuko Futaki, Yuki Hashimoto, Masanori Sugimoto
  • Nitrosated and nitrosylated prostaglandins, compositions and methods of use
    Patent number: 7772278
    Abstract: The invention describes novel nitrosated and/or nitrosylated prostaglandins, and novel compositions comprising at least one nitrosated and/or nitrosylated prostaglandin, and, optionally, at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase, and/or at least one vasoactive agent. The invention also provides novel compositions comprising at least one prostaglandin and at least one S-nitrosothiol compound, and, optionally, at least one vasoactive agent. The prostaglandin is preferably a prostaglandin E1 compound, more preferably alprostadil, and the S-nitrosothiol compound is preferably S-nitrosoglutathione.
    Type: Grant
    Filed: September 24, 2008
    Date of Patent: August 10, 2010
    Assignee: NitroMed, Inc.
    Inventors: David S. Garvey, Ricky D. Gaston, L. Gordon Letts, Inigo Saenz de Tejada, Sang William Tam, Manuel Worcel
  • SLOW RELEASE MISOPROSTOL FOR OBSTETRIC AND/OR GYNAECOLOGICAL APPLICATIONS
    Publication number: 20100197642
    Abstract: Described are medical applications of Misoprostol defined by a particular combination of sustained release or slow release dosage form and oral administration route for obstetric and/or gynaecological conditions and treatments. Further described are combination medications of Mifepristone with the aforementioned Misoprostol dosage form and administration.
    Type: Application
    Filed: April 29, 2008
    Publication date: August 5, 2010
    Inventors: Christian Fiala, Kristina Gemzell
  • NOVEL TABLET DOSAGE FORM
    Publication number: 20100196471
    Abstract: The present invention relates to novel tablet dosage forms and methods of preparing these forms, which can be used for different classes of pharmaceutical active ingredients posing stability issues in a single unit system. The dosage form includes a first layer, which includes a tablet of one or more active pharmaceutical ingredients, which is inlayed in the first layer along with other pharmaceutically acceptable excipients, and a second layer that includes one or more active pharmaceutical ingredients optionally with other pharmaceutically acceptable excipients.
    Type: Application
    Filed: March 25, 2008
    Publication date: August 5, 2010
    Inventors: Girish Kumar Jain, Ramakant Gundu, Rahul Dabre
  • Radiation Protection Using Single Wall Carbon Nanotube Derivatives
    Publication number: 20100197783
    Abstract: A method of reducing side effects of damage in a human subject exposed to radiation includes administering to the human subject carbon nanotubes in a pharmaceutically acceptable carrier after or prior to exposure to radiation. A composition for reducing radical damage includes a carbon nanotube which is functionalized (1) for substantial water solubility and (2) with a radical trapping agent appended to the carbon nanotube forming a radical scavenger-carbon nanotube conjugate.
    Type: Application
    Filed: March 26, 2008
    Publication date: August 5, 2010
    Inventors: James M. Tour, Meng Lu, Rebecca Lucente-Schultz, Ashley Leonard, Condell Dewayne Doyle, Dmitry V. Kosynkin, Brandi Katherine Price
  • TOPICAL APPLICATION OF TRAVOPROST FOR COMBATING HAIR LOSS
    Publication number: 20100190853
    Abstract: Travoprost medicament compositions for non-daily topical application are useful for simulating or inducing the growth and/or decreasing the loss and/or increasing the density and/or reducing the heterogeneity in the diameter of human hair shafts/follicles, e.g., for the treatment of androgenic alopecia, such medicament compositions being at least twice applied over a time interval of greater than 24 hours.
    Type: Application
    Filed: February 23, 2010
    Publication date: July 29, 2010
    Applicant: GALDERMA RESEARCH & DEVELOPMENT
    Inventors: Sandrine Rethore, Carine Rosignoli, André Jomard, Johannes Voegel
  • Prostaglandin derivatives
    Patent number: 7763652
    Abstract: A prostaglandin derivative represented by Formula (I): wherein X is a halogen atom in the ?- or ?-substitution, Y is an ethylene group, a vinylene group or an ethynylene group, R1 is a C3-10 cycloalkyl group, a C3-10 cycloalkyl group substituted with a C1-4 straight or branched chain alkyl group or a C4-13 cycloalkylalkyl group, R2 is a hydrogen atom or a CO2R3 group (R3 is a hydrogen atom, a C1-4 straight or branched chain alkyl group or a C2-4 straight or branched chain alkenyl group), n is an integer of 1 to 4 and p is 0, 1 or 2, a pharmaceutically acceptable salt thereof or a hydrate thereof.
    Type: Grant
    Filed: July 11, 2003
    Date of Patent: July 27, 2010
    Assignees: Taisho Pharmaceutical Co., Ltd.
    Inventors: Fumie Sato, Tohru Tanami, Makoto Yagi, Naoya Ono
  • HCV NS-3 SERINE PROTEASE INHIBITORS
    Publication number: 20100166706
    Abstract: Methods drawn to peptidomimetic compounds which inhibit the NS3 protease of the hepatitis C virus (HCV), are described. The compounds have the formula (VI) where the variable definitions are as provided in the specification. The compounds comprise a carbocyclic P2 unit in conjunction with a novel linkage to those portions of the inhibitor more distal to the nominal cleavage site of the native substrate, which linkage reverses the orientation of peptidic bonds on the distal side relative to those proximal to the cleavage site.
    Type: Application
    Filed: December 21, 2009
    Publication date: July 1, 2010
    Applicant: Medivir AB
    Inventors: Asa Rosenquist, Fredrik Thorstensson, Per-Ola Johansson, Ingemar Kvarnstrom, Bertil Samuelsson, Hans Wallberg
  • PROSTAGLANDIN PHARMACEUTICAL COMPOSITIONS
    Publication number: 20100168216
    Abstract: The present invention relates to new prostaglandin derivatives having improved pharmacological activity and enhanced tolerability. They can be employed for the treatment of glaucoma and ocular hypertension.
    Type: Application
    Filed: March 6, 2008
    Publication date: July 1, 2010
    Applicant: CTG PHARMA S.R.L.
    Inventors: Piero Del Soldato, Giancarlo Santus, Anna Sparatore
  • Therapeutic compounds
    Patent number: 7737140
    Abstract: Compounds comprising or a pharmaceutically acceptable salt or a prodrug thereof, are disclosed, wherein J1, J2, U1, B, Y, and A are as described. Methods, compositions, and medicaments related thereto are also disclosed.
    Type: Grant
    Filed: April 21, 2009
    Date of Patent: June 15, 2010
    Assignee: Allergan, Inc.
    Inventors: David W. Old, Vinh X. Ngo
  • Method for treating a disease or condition responsive to opening of C1C-2 channel
    Patent number: 7732487
    Abstract: Disclosed is a method for prophylactic or therapeutic treatment of a condition or disease responsive to opening of ClC-2 channel, which comprises the step of administrating an effective amount of a ClC-2 channel opener to a subject in need of said treatment. According to the invention, a tissue or organ to be transplanted can also be treated with the ClC-2 channel opener.
    Type: Grant
    Filed: November 18, 2002
    Date of Patent: June 8, 2010
    Assignee: Sucampo AG
    Inventor: Ryuji Ueno
  • OPHTHALMIC COMPOSITION COMPRISING A PROSTAGLANDIN
    Publication number: 20100137432
    Abstract: The present invention relates to a pharmaceutical composition suitable for ophthalmic use comprising one or more prostaglandin derivatives or salts, a stabilizing amount of polyethylene glycol hydroxystearate and pharmaceutically acceptable vehicle.
    Type: Application
    Filed: October 15, 2008
    Publication date: June 3, 2010
    Applicant: SUN PHARMA ADVANCED RESEARCH COMPANY LIMITED
    Inventors: Ajay Jaysingh Khopade, Arindam Halder, Subhas Balaram Bhowmick
  • PHARMACEUTICAL COMPOSITIONS OF DICLOFENAC AND MISOPROSTOL
    Publication number: 20100136111
    Abstract: The present invention relates to pharmaceutical compositions of diclofenac or pharmaceutically acceptable salts thereof and misoprostol or pharmaceutically acceptable salts thereof. The invention also relates to processes for the preparations of such compositions.
    Type: Application
    Filed: March 25, 2008
    Publication date: June 3, 2010
    Inventors: Ramakant Gundu, Girish Kumar Jain, Murali Narayanan, Rahul Dabre, Mandar Kodgule
  • PROSTAGLANDIN DERIVATIVES
    Publication number: 20100130507
    Abstract: Prostaglandin nitroderivatives having improved pharmacological activity and enhanced tolerability are described. They can be employed for the treatment of glaucoma and ocular hypertension.
    Type: Application
    Filed: November 6, 2009
    Publication date: May 27, 2010
    Applicant: NICOX S.A.
    Inventors: Ennio ONGINI, Valerio Chiroli, Francesca Benedini, Piero Del Soldato
  • MEDICAMENT FOR PROPHYLACTIC AND THERAPEUTIC TREATMENT OF DERMATOSIS RESULTING FROM EXCESSIVELY ADVANCED KERATINIZATION
    Publication number: 20100130603
    Abstract: A medicament for prophylactic and/or therapeutic treatment of a dermatosis resulting from excessively advanced keratinization, such as non-hereditary inflammatory keratosis and hereditary congenital keratosis, which comprises a substance selected from the group consisting of a cannabinoid agonist and a vanilloid agonist as an active ingredient.
    Type: Application
    Filed: March 7, 2008
    Publication date: May 27, 2010
    Applicant: KYOTO UNIVERSITY
    Inventor: Kenzo Takahashi
  • DERIVATIVES OF AMYRIS ALCOHOLS AND EUDESMOL FOR TREATING COLD SORES AND HERPES
    Publication number: 20100120907
    Abstract: Provided are topical formulations comprising an Amyris alcohol and/or ester derivatives of Amyris alcohol which may be used for the treatment of diseases including herpes virus infection (e.g., HSV-1, HSV-2), epidermoid carcinoma, cold sores, and human papillomavirus. Amyris alcohols contemplated for use with the present invention include valerianol, beta-eudesmol, epi-gamma-eudesmol, elemol, alpha-eudesmol, and ester derivatives thereof.
    Type: Application
    Filed: April 18, 2008
    Publication date: May 13, 2010
    Inventors: Chandra Ulagaraj Singh, Rao Jagaveerabhadra Nulu
  • EYE DROP PREPARATION COMPRISING LATANOPROST
    Publication number: 20100120908
    Abstract: Disclosed is an eye drop preparation comprising latanoprost, which is characterized in that the degradation of latanoprost in water can be prevented, the adsorption of latanoprost onto a plastic container can be prevented, and therefore the decrease in the latanoprost content can be prevented satisfactorily. The eye drop preparation comprises an eye drop composition comprising the following components (A)-(B) and packed in a plastic container: (A) latanoprost; and (B) a nonionic surfactant.
    Type: Application
    Filed: February 7, 2008
    Publication date: May 13, 2010
    Applicant: TEIKA PHARMACEUTICAL CO., LTD
    Inventors: Takahito Kimura, Joshu Watanabe, Minoru Kobayashi, Makoto Seki, Takao Shimatani, Chiharu Takagi
  • Substituted arylcyclopentenes as therapeutic agents
    Patent number: 7713968
    Abstract: Compounds comprising or a pharmaceutically acceptable salt or a prodrug thereof, are disclosed, wherein Y, A, and B are as described. Methods, compositions, and medicaments related thereto are also disclosed.
    Type: Grant
    Filed: April 22, 2009
    Date of Patent: May 11, 2010
    Assignee: Allergan, Inc.
    Inventors: Yariv Donde, Jeremiah H. Nguyen
  • Organic Compounds
    Publication number: 20100113460
    Abstract: Disclosed are compounds having the ability to inhibit cytochrome P450 2A6, 2A13, and/or 2B6 and tobacco products comprising them. Also disclosed are pharmaceutical compositions comprising them.
    Type: Application
    Filed: March 20, 2008
    Publication date: May 6, 2010
    Applicant: Givaudan SA
    Inventors: Boris Schilling, Wolf D. Woggon, Antoinette Chougnet, Thierry Granier, Georg Frater, Andreas Hanhart
  • PROSTAGLANDIN AND PROSTAMIDE DRUG DELIVERY SYSTEMS AND INTRAOCULAR THERAPEUTIC USES THEREOF
    Publication number: 20100104654
    Abstract: Biocompatible, bioerodible implants and microspheres include latanoprost and a biodegradable polymer effective, when placed intraocular (such as into the subtenon space) to treat glaucoma.
    Type: Application
    Filed: October 27, 2008
    Publication date: April 29, 2010
    Applicant: ALLERGAN, INC.
    Inventors: Michael R. Robinson, Hui Liu, Patrick M. Hughes, Lon T. Spada, Alazar N. Ghebremeskel
  • AMINO ACID SALTS OF PROSTAGLANDINS
    Publication number: 20100105771
    Abstract: The present invention is directed to novel amino acid prostaglandin salts and methods of making and using them.
    Type: Application
    Filed: October 29, 2008
    Publication date: April 29, 2010
    Inventors: Mitchell A. deLong, Jill Marie Sturdivant
  • Rupestonic acid derivatives and use thereof
    Publication number: 20100087523
    Abstract: Rupestonic acid derivatives are rupestonic acid derivative A- or B-type compounds, prepared through a condensation reaction from starting materials, i.e., a monomer compound of rupestonic acid and an aromatic amine or fatty amine or an organic alcohol, i.e., a fatty alcohol or an aromatic alcohol. Rupestonic acid, which is the monomer compound of sesquiterpene isolated from the plant Xinjiang Artemisia rupestric L., is used as a mother compound. Natural anti-virus lead compound with high activity are discovered by modifying the structure of the monomer compound of rupestonic acid. Activity results of the lead compound showed pharmaceutical application of anti-I, II flu virus and anti-I, II herpes simplex virus infection. These compounds can be used alone or in combination with one or more pharmaceutical acceptable, inert and nontoxic excipients or carries in a pharmaceutical composition.
    Type: Application
    Filed: September 15, 2009
    Publication date: April 8, 2010
    Applicant: Xinjiang Technical Institute of Physics & Chemistry, Chinese Academy of Sciences
    Inventors: Haji Akber Aisa, Jianping Yong, Jiangyu Zhao
  • Method and composition for treating periodontal disease
    Patent number: 7691862
    Abstract: The present invention is directed to a pharmaceutical composition comprising a therapeutically effective amount of misoprostol and an effective amount of an antibiotic. A suitable antibiotic is selected from the group consisting of doxycycline, gentamicin, tobramicin, ciprofloxacin, clindamycin, clarithromycin, azithromycin and metronidazole. Preferred antibiotics are doxycycline and ciprofloxacin. More preferably, the antibiotic is doxycycline. In its second aspect, the present invention is directed to a method for treating periodontal disease in a mammalian patient comprising administering to a mammalian patient in need of such treatment a therapeutically effective amount of misoprostol and an effective amount of an antibiotic. Typically, the mammalian patient is a human.
    Type: Grant
    Filed: July 2, 2007
    Date of Patent: April 6, 2010
    Assignee: Regena Therapeutics LC
    Inventors: Frank Wingrove, Rex McKee
  • Jasmonate derivative compounds pharmaceutical compounds and methods of use thereof
    Patent number: 7683211
    Abstract: The present invention provides novel jasmonate derivative compounds, methods for their preparation, pharmaceutical compositions including such compounds, and methods of using these compounds and compositions, especially as chemotherapeutic agents for treatment of cancers, especially mammalian cancers.
    Type: Grant
    Filed: August 26, 2008
    Date of Patent: March 23, 2010
    Assignee: Ramot at Tel-Aviv University Ltd.
    Inventors: Eliezer Flescher, Yoel Kashman, Dorit Reischer, Shiri Shimony
  • Novel Derivatives of Cyclic Compound And The Use Thereof
    Publication number: 20100022461
    Abstract: Disclosed is tonovel cyclic derivatives having potent inhibiting effect on melanin formation and skin hyper-pigmentation activity with no adverse response to skin. They can be used as the therapeutics for treating and preventing the skin disease caused by over-reproduced melanin.
    Type: Application
    Filed: July 2, 2007
    Publication date: January 28, 2010
    Applicant: WONKISOPHARM CO., LTD.
    Inventors: Hyun Chul Cho, Yonghyun Choi, Jonghan Yhei
  • EXTERNAL PREPARATION COMPRISING PROSTAGLANDIN DERIVATIVE
    Publication number: 20100016427
    Abstract: Provided is an external preparation comprising a complex containing: any one of a prostaglandin derivative, a pharmaceutically acceptable salt thereof and a hydrate thereof; and cyclodextrin, the prostaglandin derivative being represented by the following formula (I): (where R represents a group represented by the formula: —(CH2)4—S—CH2—CO2H, —(CH2)4—S—CH2—CO2CH3, —(CH2)4—C?C—CO2H, —CH2—S—(CH2)2—S—CH2—CO2H, or —CH2—S— (CH2)4—CO2H), so that storage stability and content uniformity of the compound of the formula (I) are ensured.
    Type: Application
    Filed: August 10, 2007
    Publication date: January 21, 2010
    Applicant: Taishio Pharmaceutical Co., Ltd.
    Inventors: Takayuki Sato, Yoshio Sato
  • USE OF AT LEAST ONE (DIHYDRO)JASMONIC ACID DERIVATIVE FOR TREATING DRY SKIN
    Publication number: 20100015080
    Abstract: A cosmetic process for treating dry skin and/or a dry scalp of non-inflammatory origin, for example, in a menopausal woman, comprising topically applying to the skin and/or the scalp a composition comprising, in a physiologically acceptable medium, at least one (dihydro)jasmonic acid derivative; novel (dihydro)jasmonic acid derivatives and to the compositions, for example, suitable for topical application to the skin, comprising them.
    Type: Application
    Filed: March 19, 2009
    Publication date: January 21, 2010
    Inventor: Maria DALKO
  • COMBINATION TREATMENT OF GLAUCOMA
    Publication number: 20090318549
    Abstract: The methods described herein provide reduction of intraocular pressure by administering a sustained release formulation including latanoprost and a pharmaceutically acceptable vehicle and administering an eye drop adjunctive composition to the eye of a patient. The sustained release formulation can release latanoprost continuously for at least 90 days from a punctum plug delivery system. The eye drop adjunctive composition can also include latanoprost.
    Type: Application
    Filed: June 24, 2009
    Publication date: December 24, 2009
    Applicant: QLT Plug Delivery, Inc.
    Inventor: Zuhal Butuner
  • Modified Release Loxoprofen Compositions
    Publication number: 20090297602
    Abstract: The invention relates to a modified release composition comprising loxoprofen or a salt or derivative thereof that in operation delivers the drug in a pulsatile or continuous manner for the treatment of pain and/or inflammation. The composition may comprise a first loxoprofen component and one subsequent loxoprofen component, wherein the first loxoprofen component comprises an immediate release component and the subsequent loxoprofen component comprises a modified release component.
    Type: Application
    Filed: May 9, 2006
    Publication date: December 3, 2009
    Inventors: John G. Devane, Paul Stark, Niall M.N. Fanning, Grvinder Singh Rekhi, Gary Liversidge, Scott Jenkins
  • METHOD FOR ENERGIZING HUMAN BEINGS
    Publication number: 20090298936
    Abstract: The present invention relates to a method for energizing a human being and to administering an energizing (personal care) composition to human beings wherein said composition contains one or more fragrance materials of group (a) of the present invention.
    Type: Application
    Filed: May 29, 2008
    Publication date: December 3, 2009
    Applicant: SYMRISE GmbH & Co. KG
    Inventors: James G. Clothier, JR., Keith McDermott, Patrice Bellon
  • Therapeutic Compounds
    Publication number: 20090281104
    Abstract: Compounds comprising or a pharmaceutically acceptable salt or a prodrug thereof, are disclosed, wherein J, B, Y, and A are as described. Methods, compositions, and medicaments related thereto are also disclosed.
    Type: Application
    Filed: May 1, 2009
    Publication date: November 12, 2009
    Applicant: ALLERGAN, INC.
    Inventors: Yariv Donde, Jeremiah H. Nguyen
  • THERAPEUTIC COMPOUNDS
    Publication number: 20090275646
    Abstract: Compounds having a structure are disclosed herein. Compositions, methods, and medicaments related to the therapeutic use of these compounds are also disclosed.
    Type: Application
    Filed: April 21, 2009
    Publication date: November 5, 2009
    Applicant: ALLERGAN, INC.
    Inventors: Yariv Donde, Jeremiah H. Nguyen, Mark Holoboski, Mari Posner, Robert M. Burk
  • THERAPEUTIC COMPOUNDS
    Publication number: 20090270396
    Abstract: Compounds comprising or a pharmaceutically acceptable salt or a prodrug thereof, are disclosed, wherein J1, J2, U1, B, Y, and A are as described. Methods, compositions, and medicaments related thereto are also disclosed.
    Type: Application
    Filed: April 21, 2009
    Publication date: October 29, 2009
    Applicant: ALLERGAN, INC.
    Inventors: David W. Old, Vinh X. Ngo
  • NOVEL DICARBOXYLIC ACID DERIVATIVES
    Publication number: 20090264469
    Abstract: The present patent application concerns new compounds of formula (I): displaying agonistic activity at sphingosine-1-phosphate (S1P) receptors, their process of preparation and their use as immunosuppressive agents.
    Type: Application
    Filed: October 18, 2005
    Publication date: October 22, 2009
    Applicants: BIO-PROJET, SUN PHARMACEUTICAL INDUSTRIES LTD.
    Inventors: Marc Capet, Nicolas Levoin, Isabelle Berrebi-Bertrand, Olivia Poupardin, Philippe Robert, Jean-Charles Schwartz, Jeanne-Marie Lecomte, Thennati Rajamannar, Ranjan Kumar Pal, Biswajit Samanta, Jignesh K. Jivani, Bhavesh M. Panchal, Isha H. Bhatt, Jayraj D. Aradhye
  • Method for Prevention of Degradation of Thermally Unstable Medicament
    Publication number: 20090264523
    Abstract: The present invention provides a method for preventing the degradation of a thermally unstable medicament in an eye drop containing the medicament thereby to stabilize the eye drop. By adding an organic amine to an eye drop containing a thermally unstable medicament, the degradation of the medicament in the eye drop can be effectively prevented, and therefore the eye drop can be stably stored.
    Type: Application
    Filed: August 2, 2006
    Publication date: October 22, 2009
    Inventors: Hiroyuki Asada, Akio Kimura
  • THERAPEUTIC SUBSTITUTED CYCLOPENTANES
    Publication number: 20090239869
    Abstract: Therapeutic compounds are disclosed herein. Methods, compositions, and medicaments related thereto are also disclosed. The compounds described herein are used to treat ocular conditions, bowel disease and baldness.
    Type: Application
    Filed: March 16, 2009
    Publication date: September 24, 2009
    Applicant: ALLERGAN, INC.
    Inventors: Yariv Donde, Robert M. Burk, Jeremiah H. Nguyen
  • PHARMACEUTICAL COMPOSITIONS HAVING DESIRABLE BIOAVAILABILITY
    Publication number: 20090234004
    Abstract: The present invention is directed to the provision of pharmaceutical compositions. The compositions include a therapeutic agent and a relatively low amount of surfactant for providing higher bioavailability of the therapeutic agent. The compositions are particularly desirable as ophthalmic compositions in which the therapeutic agent is a prostaglandin such as travoprost and the surfactant is a vegetable oil such as castor oil.
    Type: Application
    Filed: March 13, 2009
    Publication date: September 17, 2009
    Inventors: Bhagwati P. Kabra, Nuria Carreras, Monica Cuchi, Francisco Javier Galan, Mridvika, Elena Gonzalez Puig, Nuria Jimenez, Carmen Martinez
  • THERAPEUTIC CYCLOPENTANE DERIVATIVES
    Publication number: 20090233921
    Abstract: Compounds comprising or a pharmaceutically acceptable salt or a prodrug thereof, are disclosed, wherein Y, A, and B are as described. Methods, compositions, and medicaments related thereto are also disclosed.
    Type: Application
    Filed: March 6, 2009
    Publication date: September 17, 2009
    Applicant: ALLERGAN, INC.
    Inventor: Yariv Donde
  • AQUEOUS PHARMACEUTICAL COMPOSITIONS CONTAINING BORATE-POLYOL COMPLEXES
    Publication number: 20090232763
    Abstract: The present invention is directed to the provision of multi-dose, ophthalmic compositions. The compositions possess sufficient antimicrobial activity to satisfy USP preservative efficacy requirements, as well as similar preservative standards (e.g., EP and JP). The compositions include at two different polyols in conjunction with borate, a preservative or both.
    Type: Application
    Filed: March 3, 2009
    Publication date: September 17, 2009
    Inventors: Bhagwati P. Kabra, Rajni Jani
  • NON-ACIDIC CYCLOPENTANE HEPTANOIC ACID, 2-CYCLOALKYL OR ARYLALKYL DERIVATIVES AS THERAPEUTIC AGENTS
    Publication number: 20090227672
    Abstract: The present invention provides cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl compounds, which may be substituted in the 1-position with amino, amido, ether or ester groups, e.g., a 1-OH cyclopentane heptanoic acid, 2-(cycloalkyl or arylalkyl) compound. The cyclopentane heptanoic acid, 2-(cycloalkyl or arylalkyl) compounds of the present invention are potent ocular hypotensives, and are particularly suitable for the management of glaucoma. Moreover, the cyclopentane heptanoic, 2-(cycloalkyl or arylalkyl) compounds of this invention are smooth muscle relaxants with broad application in systemic hypertensive and pulmonary diseases; smooth muscle relaxants with application in gastrointestinal disease, reproduction, fertility, incontinence, shock, etc.
    Type: Application
    Filed: December 19, 2008
    Publication date: September 10, 2009
    Inventors: David F. Woodward, Steven W. Andrews, Robert M. Burk, Michael E. Garst
  • Therapeutic substituted cyclopentanes
    Patent number: 7585895
    Abstract: Therapeutic prostaglandin compounds are disclosed herein.
    Type: Grant
    Filed: August 14, 2008
    Date of Patent: September 8, 2009
    Assignee: Allergan, Inc.
    Inventors: Yariv Donde, Robert M. Burk
  • 9-chloro-15-deoxyprostaglandin derivatives, process for their preparation and their use as medicaments
    Patent number: 7563924
    Abstract: The present invention relates to 9-chloroprostaglandin derivatives of the general formula I which may be advantageous for the treatment of fertility problems.
    Type: Grant
    Filed: November 20, 2006
    Date of Patent: July 21, 2009
    Assignee: Schering Aktiengesellschaft
    Inventors: Bernd Buchmann, Daryl Faulds, William Guilford, Gernot Langer, Judy Li, Bernhard Lindenthal, Werner Skuballa, Luisella Toschi
  • MICELLAR COMPOSITIONS WITH OPHTHALMIC APPLICATIONS
    Publication number: 20090169629
    Abstract: This invention relates to micellar compositions comprising at least one pharmaceutically active substance and a mixture of n-alkyl dimethyl benzyl ammonium chlorides, wherein the mixture comprises more than 30% n-alkyl dimethyl benzyl ammonium chlorides having a chain length superior or equal to C16. This invention also relates to ophthalmic compositions containing such micellar compositions and methods of using these ophthalmic compositions for the treatment of eye conditions.
    Type: Application
    Filed: January 2, 2008
    Publication date: July 2, 2009
    Applicant: NOVAGALI PHARMA SA
    Inventors: Gregory LAMBERT, Frederic LALLEMAND, Laura RABINOVICH-GUILATT, Severine BAGUE, Jean-Sebastien GARRIGUE
  • Chronotherapeutic Ocular Delivery System Comprising a Combination of Prostaglandin and a Beta-Blocker for Treating Primary Glaucoma
    Publication number: 20090155338
    Abstract: Chronotherapeutic delivery system for treating primary open-angle glaucoma, comprising a delivery system incorporating pharmaceutical products for delivery to an eye in the treatment of primary open-angle glaucoma (POAG), comprising: (a) a biocompatible erodible material incorporating a therapeutically-effective amount of a prostaglandin analogue, and (b) a reservoir containing a therapeutically-effective amount of a beta-blocker, whereby, when the delivery system is placed in the eye the prostaglandin analogue is delivered gradually as the erodible material is eroded, and the beta-blocker is delivered rapidly when at least a predetermined portion of the erodible material has been eroded.
    Type: Application
    Filed: September 11, 2006
    Publication date: June 18, 2009
    Applicant: ASTON UNIVERSITY
    Inventors: Barbara R. Conway, Doina Gherghel
  • Prostaglandin reductase inhibitors
    Publication number: 20090124688
    Abstract: A method of inhibiting 15-keto prostaglandin-?13-reductase 2 by contacting 15-keto prostaglandin-?13-reductase 2 with an aryl compound of Formula (I), (II), (III), or (IV) shown herein. Also disclosed are methods of treating peroxisome proliferators-activated receptor related diseases and lowering blood glucose levels by administering to a subject in need thereof an effective amount of such an aryl compound.
    Type: Application
    Filed: January 8, 2007
    Publication date: May 14, 2009
    Inventors: Rong-Hwa Lin, Leewen Lin, Shih-Yao Lin, Shu-Hua Lee
  • Prostaglandin Analog Compositions And Methods To Treat Epithelial-Related Conditions
    Publication number: 20090111761
    Abstract: The present invention relates to the formulation and delivery of prostaglandin analogs to treat epithelial-related condition. In some embodiments, the compositions of the invention are used to stimulate hair growth. In some embodiments, the compositions of the invention are used to restore hair color to depigmented hair. The present invention further relates to the formulation and delivery of prostaglandin analogs to reduce intraocular pressure.
    Type: Application
    Filed: September 23, 2008
    Publication date: April 30, 2009
    Inventors: Pamela Lipkin, Beverly Lubit